Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Analysis of Sequential Docetaxel and Enzalutamide in mCRPC
NCT03700099Phase 2Active, not recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Sep 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoints: PSA Response Rate (>50% decline) after Docetaxel at 6 months and PSA Response Rate (>50% decline) after Enzalutamide at 12 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03700099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700099.